Table 1.
Clinical outcomes of FAP targeted radionuclide therapy
| Year | Author | Drug | Total GBq | N | Tumor | Response | Side effects | Tumor dosimetry (Gy/GBq) | Bone marrow dosimetry (Gy/GBq) | Kidney dosimetry (Gy/GBq) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018 | Linder et al. [17] | [90Y]Y-FAPI-04 | 2.9 | 1 | Breast | Less pain | None | NR | NR | NR |
| 2021 | Kuyumcu et al. [18] | [177Lu]Lu-FAPI-04 | 0.27 | 4 | Breast, thymus, thyroid, and ovarium | NR | NR | 0.62 | 0.002 | 0.25 |
| 2020 | Linder et al. [21] | [90Y]Y-FAPI-46 | 6 | 2 | Ovarium and pancreas | NR | NR | NR | NR | NR |
| 2021 | Kratochwil et al. [22] | [153Sm]Sm/[90Y]Y-FAPI-46 | 20 + 8 | 1 | Sarcoma | Stable disease | None | NR | NR | NR |
| 2021 | Rathke et al. [23] | [90Y]Y-FAPI-46 | Up to 28.1 | 1 | Colorectal and breast | Mixed response | None | NR | NR | NR |
| 2021 | Assadi et al. [24] | [177Lu]Lu-FAPI-46 | 1.85–4.44 | 18 | Various (breast, colon, ovarium, etc.) | NR | 1p grade I–III hematotoxicity | NR | NR | 0.886 |
| 2022 | Kaghazchi et al. [25] | [177Lu]Lu-FAPI-46 | 1.85 | 1 | Pancreas | NR | None | NR | NR | NR |
| 2022 | Barashki et al. [26] | [177Lu]Lu-FAPI-46 | 7.4 | 1 | Multiple endocrine neoplasia type 2A | Clinical improvement | None | NR | NR | NR |
| 2022 | Fu et al. [27] | [177Lu]Lu-FAPI-46 | 22.3 | 1 | Radioiodine-refractory thyroid cancer | NR | None | NR | NR | NR |
| 2022 | Fu et al. [28] | [177Lu]Lu-FAPI-46 | 3.7 | 1 | Nasopharyngeal | Mixed response | None | NR | NR | NR |
| 2022 | Ferdinandus et al. [29] | [90Y]Y-FAPI-46 | 3.8–7.8 | 10 | Pancreas and sarcoma | NR | 4p grade III hematotoxicity | 1.28 | 0.04 | 0.52 |
| 2022 | Fendler et al. [30] | [90Y]Y-FAPI-46 | 3.7–7.4 | 21 | Sarcoma, pancreas, prostate, gastric | 1p partial response, 7p stable disease | 8p (38%) grade > III mostly hematotoxicity | 2.81 | 0.04 | 0.53 |
| 2021 | Baum et al. [33] | [90Y]Y-FAP-2286 | 5.8 | 11 | Pancreas, breast, rectum, and ovarium | 2p with stable disease, 3p pain relief | 3p grade III, mostly hematotoxicity | 3 | 0.05 | 1 |
| 2022 | McConathy et al. [34] | [177Lu]-FAP-2286 | 3.7 | 3 | Colorectal and peritoneal | NR | No grade III/IV | NR | NR | NR |
| 2021 | Ballal et al. [36] | [177Lu]Lu-DOTA.SA.FAPI | 3.2 | 1 | Breast | Less pain | None | 1.48-3.46 | NR | NR |
| 2021 | Ballal et al. [37] | [177Lu]Lu-DOTA.SA.FAPI | 2.96 | 3 | Breast | NR | NR | 0.6 | 0.001 | 0.62 |
| 2021 | Ballal et al. [37] | [177Lu]Lu-DOTAGA.(SA.FAPI)2 | 1.48 | 7 | Thyroid, breast, and paraganglioma | NR | NR | 6.7 | 0.02 | 0.37 |
| 2022 | Ballal et al. [38] | [177Lu]Lu-DOTAGA.(SA.FAPI)2 | 8.2 | 15 | Radioiodine-refractory differentiated thyroid cancer | 4p with partial response, 3p with stable disease | No grade III/IV | 10.8 | 0.3 | 0.026 |
NR, not reported; P, patients